ArticleBMC psychiatry2016
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
Article in BMC psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrated Biological Markers for the Prediction of Treatment Response in Depression
A Collaborative Investigation of Predictors of Relapse in Major Depressive Disorder: CAN-BIND-1 Extension Study
CAN-BIND (Canadian Biomarker Integration Network for Depression): Long-Term Follow Up Study
Integrated Biological Markers for the Prediction of Treatment Response in Depression: Validation Study
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.
- Electroencephalographic Biomarkers for Treatment Response Prediction in Major Depressive Illness: A Meta-Analysis.The American journal of psychiatry · 2019Pooled it
- Transient frontal spectral events from EEG predict antidepressant response to sertraline in depression.Journal of psychiatric research · 2026Trial
- Generalizability of Treatment Outcome Prediction Across Antidepressant Treatment Trials in Depression.JAMA network open · 2025Trial
- Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication.JAMA network open · 2023Trial
- The Differential Relation of Emotional, Physical, and Sexual Abuse Histories to Antidepressant Treatment Remission and Persistence of Anhedonia in Major Depression: A CAN-BIND-1 Report.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Trial
- Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report.Cerebral cortex (New York, N.Y. : 1991) · 2022Trial
- Trial
- MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.Nature communications · 2017Trial
- Neurophysiological Correlates of Neuroanatomical Dimensions in Major Depressive Disorder: Electroencephalographic Markers of Brain Function and Treatment Outcome.Biological psychiatry global open science · 2026Article
- Deep learning using electroencephalogram (EEG) data for diagnosing and predicting SSRI response in major depressive disorder.Communications medicine · 2026Article
- Socioeconomic Status Is Associated With Reward Processing, Interleukin 1β, Striatal Connectivity, and Antidepressant Outcomes in Individuals With Major Depressive Disorder: A CAN-BIND-1 Report.Biological psychiatry global open science · 2026Article
- Transient frontal spectral events from EEG predict antidepressant response to sertraline in depression.medRxiv : the preprint server for health sciences · 2026Article
- Generalizable structure-function covariation predictive of antidepressant response revealed by target-oriented multimodal fusion.Nature. Mental health · 2026Article
- Which aspects of anhedonia predict response to pharmacotherapy in major depressive disorder?Psychological medicine · 2025Article
- Neuroanatomical dimensions in major depression linked to cognition, adverse life events, self-harm, metabolomics and genetics.Communications medicine · 2025Article
- Early Brain Functional Connectivity Changes Induced by Antidepressants and Placebo.bioRxiv : the preprint server for biology · 2025Article
- Latent Profile Analysis of Childhood Maltreatment and Neural Markers in Depression.JAMA network open · 2025Article
- Framing major depressive disorder as a condition of network imbalance at the compartment level: a proof-of-concept study.Cerebral cortex (New York, N.Y. : 1991) · 2025Article
- Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Shared and unique transcriptomic signatures of antidepressant and probiotics action in the mammalian brain.Molecular psychiatry · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 12 institutions in 3 countries.
Funding
Abstract
backgroundMajor Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers ("biomarkers") of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD.
methodsCAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10-20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2-10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. DISCUSSION: From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD. Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice and clinical outcomes. It will also create an innovative, robust platform and database for future research.
trial registrationClinicalTrials.gov identifier NCT01655706 . Registered July 27, 2012.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.